Your browser doesn't support javascript.
loading
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
Prelaj, Arsela; Boeri, Mattia; Robuschi, Alessandro; Ferrara, Roberto; Proto, Claudia; Lo Russo, Giuseppe; Galli, Giulia; De Toma, Alessandro; Brambilla, Marta; Occhipinti, Mario; Manglaviti, Sara; Beninato, Teresa; Bottiglieri, Achille; Massa, Giacomo; Zattarin, Emma; Gallucci, Rosaria; Galli, Edoardo Gregorio; Ganzinelli, Monica; Sozzi, Gabriella; de Braud, Filippo G M; Garassino, Marina Chiara; Restelli, Marcello; Pedrocchi, Alessandra Laura Giulia; Trovo', Francesco.
Affiliation
  • Prelaj A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Boeri M; Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.
  • Robuschi A; Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Ferrara R; Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.
  • Proto C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Lo Russo G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Galli G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • De Toma A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Brambilla M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Occhipinti M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Manglaviti S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Beninato T; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Bottiglieri A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Massa G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Zattarin E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Gallucci R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Galli EG; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Ganzinelli M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Sozzi G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • de Braud FGM; Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Garassino MC; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Restelli M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
  • Pedrocchi ALG; Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.
  • Trovo' F; Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.
Cancers (Basel) ; 14(2)2022 Jan 16.
Article in En | MEDLINE | ID: mdl-35053597
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: Italy